(주)앤투비

{
  "address": "서울특별시 노원구",
  "ceo_name": "박명환",
  "certificate": [
    {
      "cert_number": "20200105253",
      "changes": "",
      "disclosure_date": "2020-04-24",
      "first_cert_date": "2020-04-24",
      "no": "1",
      "type": "기술평가보증기업(기금)",
      "valid_period": "2020-04-24 ~ 2022-04-23"
    },
    {
      "cert_number": "20220615020066",
      "changes": "",
      "disclosure_date": "2022-06-15",
      "first_cert_date": "2020-04-24",
      "no": "2",
      "type": "연구개발유형",
      "valid_period": "2022-04-24 ~ 2025-04-23"
    },
    {
      "cert_number": "20250513020009",
      "changes": "",
      "disclosure_date": "2025-05-13",
      "first_cert_date": "2020-04-24",
      "no": "3",
      "type": "연구개발유형",
      "valid_period": "2025-04-24 ~ 2028-04-23"
    }
  ],
  "company_name": "(주)앤투비",
  "corp_no": "110111-*******",
  "financials": {
    "2022": {
      "capital_stock": 150000000,
      "cost_of_sales": 46103000,
      "current_assets": 71500000,
      "current_liabilities": 18244000,
      "gross_profit": 29187000,
      "net_income": -33986000,
      "net_income_bs": -33985000,
      "non_current_assets": 201364000,
      "non_current_liabilities": 200000000,
      "non_operating_expenses": 354712000,
      "non_operating_income": 355496000,
      "operating_profit": -34770000,
      "revenue": 75290000,
      "sga_expenses": 63957000,
      "total_assets": 272863000,
      "total_equity": 54619000,
      "total_liabilities": 218244000
    },
    "2023": {
      "capital_stock": 150000000,
      "cost_of_sales": 71223000,
      "current_assets": 56158000,
      "current_liabilities": 19289000,
      "gross_profit": 19354000,
      "net_income": 5762000,
      "net_income_bs": 5763000,
      "non_current_assets": 219409000,
      "non_current_liabilities": 200000000,
      "non_operating_expenses": 307179000,
      "non_operating_income": 393177000,
      "operating_profit": -80236000,
      "revenue": 90577000,
      "sga_expenses": 99589000,
      "total_assets": 275567000,
      "total_equity": 56278000,
      "total_liabilities": 219289000
    },
    "2024": {
      "capital_stock": 150000000,
      "cost_of_sales": 59744000,
      "current_assets": 61286000,
      "current_liabilities": 82541000,
      "gross_profit": 24718000,
      "net_income": -25524000,
      "net_income_bs": -25524000,
      "non_current_assets": 252010000,
      "non_current_liabilities": 200000000,
      "non_operating_expenses": 146174000,
      "non_operating_income": 188218000,
      "operating_profit": -67568000,
      "revenue": 84462000,
      "sga_expenses": 92286000,
      "total_assets": 313295000,
      "total_equity": 30755000,
      "total_liabilities": 282541000
    }
  },
  "industry": "의학 및 약학 연구개발업",
  "investment": [],
  "main_products": "의료용 화합물 제조",
  "phone": "010-8200-****",
  "years": [
    2024,
    2023,
    2022
  ]
}